Literature DB >> 10777513

Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor.

M Shimizu1, J T Potts, T J Gardella.   

Abstract

The amino-terminal and carboxyl-terminal portions of the 1-34 fragment of parathyroid hormone (PTH) contain the major determinants of receptor activation and receptor binding, respectively. We investigated how the amino-terminal signaling portion of PTH interacts with the receptor by utilizing analogs of the weakly active fragment, rat (r) PTH(1-14)NH(2), and cells transfected with the wild-type human PTH-1 receptor (hP1R-WT) or a truncated PTH-1 receptor which lacked most of the amino-terminal extracellular domain (hP1R-delNt). Of 132 mono-substituted PTH(1-14) analogs, most having substitutions in the (1-9) region were inactive in assays of cAMP formation in LLC-PK1 cells stably expressing hP1R-WT, whereas most having substitutions in the (10-14) region were active. Several substitutions (e.g. Ser(3) --> Ala, Asn(10) --> Ala or Gln, Leu(11) --> Arg, Gly(12) --> Ala, His(14) --> Trp) enhanced activity 2-10-fold. These effects were additive, as [Ala(3),(10,12),Arg(11), Trp(14)] rPTH(1-14)NH(2) was 220-fold more potent than rPTH(1-14)NH(2) (EC(50) = 0.6 +/- 0.1 and 133 +/- 16 micrometer, respectively). Native rPTH(1-11) was inactive, but [Ala(3,10), Arg(11)]rPTH(1-11)NH(2) achieved maximal cAMP stimulation (EC(50) = 17 micrometer). The modified PTH fragments induced cAMP formation with hP1R-delNt in COS-7 cells as potently as they did with hP1R-WT; PTH(1-34) was 6,000-fold weaker with hP1R-delNt than with hP1R-WT. The most potent analog, [Ala(3,10,12),Arg(11), Trp(14)]rPTH(1-14)NH(2), stimulated inositol phosphate production with hP1R-WT. The results show that short NH(2)-terminal peptides of PTH can be optimized for considerable gains in signaling potency through modification of interactions involving the regions of the receptor containing the transmembrane domains and extracellular loops.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777513     DOI: 10.1074/jbc.M909861199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  Interaction of PTH and PTHrP with their receptors.

Authors:  T J Gardella; H Jüppner
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

3.  Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism.

Authors:  Marián Castro; Viacheslav O Nikolaev; Dieter Palm; Martin J Lohse; Jean-Pierre Vilardaga
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-18       Impact factor: 11.205

4.  Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Authors:  Makoto Okazaki; Sebastien Ferrandon; Jean-Pierre Vilardaga; Mary L Bouxsein; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

5.  Complexity in differential peptide-receptor signaling: response to Segonzac et Al. and Mueller et Al. commentaries.

Authors:  Horim Lee; Ashok Khatri; Julia M Plotnikov; Xue-Cheng Zhang; Jen Sheen
Journal:  Plant Cell       Date:  2012-08-24       Impact factor: 11.277

Review 6.  Non-canonical signaling of the PTH receptor.

Authors:  Jean-Pierre Vilardaga; Thomas J Gardella; Vanessa L Wehbi; Timothy N Feinstein
Journal:  Trends Pharmacol Sci       Date:  2012-06-16       Impact factor: 14.819

7.  Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations.

Authors:  Thomas Dean; Agnes Linglart; Matthew J Mahon; Murat Bastepe; Harald Jüppner; John T Potts; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2005-12-08

8.  Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist.

Authors:  Ross W Cheloha; Tomoyuki Watanabe; Thomas Dean; Samuel H Gellman; Thomas J Gardella
Journal:  ACS Chem Biol       Date:  2016-08-17       Impact factor: 5.100

Review 9.  PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.

Authors:  Ross W Cheloha; Samuel H Gellman; Jean-Pierre Vilardaga; Thomas J Gardella
Journal:  Nat Rev Endocrinol       Date:  2015-08-25       Impact factor: 43.330

10.  Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Authors:  Ross W Cheloha; Bingming Chen; Niyanta N Kumar; Tomoyuki Watanabe; Robert G Thorne; Lingjun Li; Thomas J Gardella; Samuel H Gellman
Journal:  J Med Chem       Date:  2017-10-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.